Efficacy of Ranolazine in treating ventricular premature beats

Comparison of the efficacy of Ranolazine with placebo for reducing ventricular premature beats (VPBs) in patients with high burden of VPBs in holter monitoring

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220515054863N2

Enrollment

Registered

2022-11-01

Start date

2022-12-01

Completion date

Unknown

Last updated

2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

premature ventricular beats, ventricular premature depolarization, premature ventricular complexes, premature ventricular contraction. Ventricular premature depolarization

Interventions

Intervention 1: Intervention group: Drug name: Ranolazine, formula: C24H33N3O4, dose: 1000 mg Bid for 30 days, company: Koushan Pharmed. Intervention 2: Control group: placebo, company: Koushan Pharme

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Minimum age of 18 PVC burden between 10 to 30 percent among whole beats

Exclusion criteria

Exclusion criteria: Patients with Atrial Fibrillation (AF) Patients diagnosed with ischemic ventricular tachycardia (VT) Patients with a history of serious ventricular tachyarrhythmias in the past 4 weeks (e.g., sustained ventricular tachycardia and ventricular fibrillation) Patients who have a QT interval higher than 550 milliseconds or consume medications that prolong the QT interval Patients with a heart transplant Patients undergoing dialysis Patients with a creatinine clearance below 30 ml/min or a blood creatinine over 2.5 mg/dl Patients with moderate to severe hepatic dysfunction Patients receiving metformin with a dose extending 1000 mg Bid Patients receiving simvastatin with a daily dose extending 20 mg Patients receiving Dabigatran Patients receiving a CYP3A4 inhibitor (Ketoconazole, Clarithromycin, Ritonavir, Diltiazem, Fluconazole, Erythromycin, Verapamil or grapefruit juice) Patients with a history of Ranolazine consumption in the past two months Patients who have previously discontinued Ranolazine due to side effects Pregnant or breastfeeding patients, or patients planning for pregnancy during the study period Patients without informed consent

Design outcomes

Primary

Measure	Time frame
Difference in PVC burden on holter before and after treatment. Timepoint: 30 days. Method of measurement: Holter monitoring at the time of enrollment and 30 days after receiving therapy.	—

Secondary

Measure	Time frame
Any patient-reported side effects. Timepoint: 30 days. Method of measurement: interview.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMasih Tajdini

Tehran University of Medical Sciences

mtajdini@sina.tums.ac.ir+98 21 8802 9600

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026